The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the cornerstone of a curative treatment strategy for diffuse malignant peritoneal mesothelioma (DMPM).
All patients with a diagnostic of DMPM should be evaluated prior any treatment in an expert peritoneal surface malignancies (PSM) centre.
Upfront surgery appears preferable to neoadjuvant chemotherapy in patients amenable to complete CRS.